- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
WASHINGTON — The Alzheimer’s Association stunned Washington last month when it urged Biogen to lower the price of its new Alzheimer’s drug — an extremely rare rebuke on drug pricing from a
patient advocacy group, most of which normally sidestep the topic. Pharma’s fiercest critics here — many of whom have blasted patient advocacy groups for not being more involved in the drug
pricing debate — celebrated the Alzheimer’s Association’s audacity, especially as it risked being blackballed by its pharma funders. The statement made it clear that Biogen, as one crisis
communications expert put it, “can’t afford to alienate its biggest cheerleader.” But not everyone is ready to believe that the Alzheimer’s Association is actually pushing the company to cut
the drug’s $56,000 annual price tag. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY INTELLIGENCE ON
CAPITOL HILL AND THE LIFE SCIENCES INDUSTRY — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to
STAT+. Subscribe
